Table 1.
Baseline parameters
| PAD Patients |
Healthy Subjects |
|||
|---|---|---|---|---|
| Preketorolac | Postketorolac | Preketorolac | Postketorolac | |
| Men/women | 5/2 | 5/2 | ||
| Age, yr | 65 ± 2 | 65 ± 2 | ||
| Height, cm | 173 ± 4 | 172 ± 4 | ||
| Weight, kg | 78 ± 5 | 76 ± 4 | ||
| Body mass index, kg/m2 | 26.0 ± 1.0 | 25.6 ± 0.8 | ||
| ABI most | 0.54 ± 0.07† | 1.10 ± 0.06 | ||
| ABI least | 0.76 ± 0.10† | 1.09 ± 0.04 | ||
| Systolic blood pressure, mmHg | 129 ± 4† | 135 ± 7 | 116 ± 4 | 121 ± 5 |
| Diastolic blood pressure, mmHg | 77 ± 2 | 78 ± 3 | 74 ± 3 | 75 ± 3 |
| Mean arterial pressure, mmHg | 98 ± 3† | 94 ± 3 | 84 ± 5 | 91 ± 3* |
| Heart rate, beats/min | 58 ± 2 | 56 ± 2 | 57 ± 3 | 54 ± 3 |
Values are means ± SE; n = 7 peripheral arterial disease (PAD) patients and 7 healthy control subjects. ABI most, ankle-brachial index of the most symptomatic leg; ABI least, ankle-brachial index of the least symptomatic leg.
*
Difference between preketorolac and postketorolac in healthy subjects; †difference between groups at the specific time point (P < 0.05).